APPLICATION
Application Note
*Optimal dilutions/concentrations should be determined by the researcher.
| Application |
Recommended Dilution |
| 1:100~1:500 |
| 1:50~1:100 |
Not tested in other applications.
Calculated MW
PROPERTIES
Form
Liquid
Buffer
PBS (without Mg²⁺ and Ca²⁺) pH7.4, 150mM NaCl, 50% Glycerol
Preservative
0.02% Sodium azide
Storage
Store as concentrated solution. Centrifuge briefly prior to opening vial. For short-term storage (1-2 weeks), store at 4ºC. For long-term storage, aliquot and store at -20ºC or below. Avoid multiple freeze-thaw cycles.
Concentration
Batch dependent (Please refer to the vial label for the specific concentration.)
Antigen Species
Human
Immunogen
The antiserum was produced against synthesized peptide derived from human F13B (61-110).
Purification
Purified by antigen-affinity chromatography
From serum
Conjugation
Unconjugated
Note
For laboratory use only. Not for any clinical, therapeutic, or diagnostic use in humans or animals. Not for animal or human consumption.
TARGET
Synonyms
F13B , FXIIIB , coagulation factor XIII B chain , Factor XIII B
Cellular Localization
Secreted
Background
This gene encodes coagulation factor XIII B subunit. Coagulation factor XIII is the last zymogen to become activated in the blood coagulation cascade. Plasma factor XIII is a heterotetramer composed of 2 A subunits and 2 B subunits. The A subunits have catalytic function, and the B subunits do not have enzymatic activity and may serve as a plasma carrier molecules. Platelet factor XIII is comprised only of 2 A subunits, which are identical to those of plasma origin. Upon activation by the cleavage of the activation peptide by thrombin and in the presence of calcium ion, the plasma factor XIII dissociates its B subunits and yields the same active enzyme, factor XIIIa, as platelet factor XIII. This enzyme acts as a transglutaminase to catalyze the formation of gamma-glutamyl-epsilon-lysine crosslinking between fibrin molecules, thus stabilizing the fibrin clot. Factor XIII deficiency is classified into two categories: type I deficiency, characterized by the lack of both the A and B subunits; and type II deficiency, characterized by the lack of the A subunit alone. These defects can result in a lifelong bleeding tendency, defective wound healing, and habitual abortion. [provided by RefSeq, Jul 2008]
Database
Research Area
DATA IMAGES
|
GTX87291 IHC-P Image
IHC-P analysis of human heart tissue using GTX87291 F13B antibody. The picture on the right is blocked with the synthesized peptide.
|
|
|
GTX87291 ICC/IF Image
ICC/IF analysis of HUVEC cells using GTX87291 F13B antibody. The picture on the right is blocked with the synthesized peptide.
|
REFERENCE
There are currently no references for Factor XIIIb antibody (GTX87291). Be the first to share your publications with this product.
REVIEW
There are currently no reviews for Factor XIIIb antibody (GTX87291). Be the first to share your experience with this product.
